Efficacy of invasive and non-invasive methods for the treatment of Parkinson's disease: Nanodelivery and enriched environment.

Autor:	Vaquero-Rodríguez A; Department of Neurosciences, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain; Neurodegenerative diseases Group, Biocruces Health Research Institute, Barakaldo, Bizkaia, Spain., Razquin J; Neurodegenerative diseases Group, Biocruces Health Research Institute, Barakaldo, Bizkaia, Spain; Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain., Zubelzu M; Neurodegenerative diseases Group, Biocruces Health Research Institute, Barakaldo, Bizkaia, Spain; Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain., Bidgood R; Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain., Bengoetxea H; Department of Neurosciences, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain; Neurodegenerative diseases Group, Biocruces Health Research Institute, Barakaldo, Bizkaia, Spain., Miguelez C; Neurodegenerative diseases Group, Biocruces Health Research Institute, Barakaldo, Bizkaia, Spain; Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain., Morera-Herreras T; Neurodegenerative diseases Group, Biocruces Health Research Institute, Barakaldo, Bizkaia, Spain; Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain., Ruiz-Ortega JA; Neurodegenerative diseases Group, Biocruces Health Research Institute, Barakaldo, Bizkaia, Spain; Department of Pharmacology, Faculty of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria, Spain., Lafuente JV; Department of Neurosciences, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain; Neurodegenerative diseases Group, Biocruces Health Research Institute, Barakaldo, Bizkaia, Spain., Ortuzar N; Department of Neurosciences, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain; Neurodegenerative diseases Group, Biocruces Health Research Institute, Barakaldo, Bizkaia, Spain. Electronic address: naiara.ortuzar@ehu.eus.
Jazyk:	angličtina
Zdroj:	International review of neurobiology [Int Rev Neurobiol] 2023; Vol. 172, pp. 103-143. Date of Electronic Publication: 2023 Jun 08.
DOI:	10.1016/bs.irn.2023.05.010
Abstrakt:	Parkinson's disease (PD) is the second most common neurodegenerative disorder characterised by the loss of dopaminergic neurons in the substantia nigra pars compacta and the subsequent motor disability. The most frequently used treatments in clinics, such as L-DOPA, restore dopaminergic neurotransmission in the brain. However, these treatments are only symptomatic, have temporary efficacy, and produce side effects. Part of the side effects are related to the route of administration as the consumption of oral tablets leads to unspecific pulsatile activation of dopaminergic receptors. For this reason, it is necessary to not only find alternative treatments, but also to develop new administration systems with better security profiles. Nanoparticle delivery systems are new administration forms designed to reach the pharmacological target in a highly specific way, leading to better drug bioavailability, efficacy and safety. Some of these delivery systems have shown promising results in animal models of PD not only when dopaminergic drugs are administered, but even more when neurotrophic factors are released. These latter compounds promote maturation and survival of dopaminergic neurons and can be exogenously administered in the form of pharmacological therapy or endogenously generated by non-pharmacological methods. In this sense, experimental exposure to enriched environments, a non-invasive strategy based on the combination of social and inanimate stimuli, enhances the production of neurotrophic factors and produces a neuroprotective effect in parkinsonian animals. In this review, we will discuss new nanodelivery systems in PD with a special focus on therapies that increase the release of neurotrophic factors. (Copyright © 2023. Published by Elsevier Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu